Cargando…
Targeting telomerase with radiolabeled inhibitors
The expression of telomerase in approximately 85% of cancers and its absence in the majority of normal cells makes it an attractive target for cancer therapy. However the lag period between initiation of telomerase inhibition and growth arrest makes direct inhibition alone an insufficient method of...
Autores principales: | Waghorn, Philip A., Jackson, Mark R., Gouverneur, Veronique, Vallis, Katherine A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editions Scientifiques Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154340/ https://www.ncbi.nlm.nih.gov/pubmed/27657809 http://dx.doi.org/10.1016/j.ejmech.2016.09.028 |
Ejemplares similares
-
Oligonucleotide-Functionalized Gold Nanoparticles
for Synchronous Telomerase Inhibition, Radiosensitization, and Delivery
of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2021) -
Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021) -
Radiolabeled Cationic Peptides for Targeted Imaging of Infection
por: Aweda, Tolulope A., et al.
Publicado: (2019) -
Structural Investigations, Cellular Imaging, and Radiolabeling
of Neutral, Polycationic, and Polyanionic Functional Metalloporphyrin
Conjugates
por: Ciaffaglione, Valeria, et al.
Publicado: (2021) -
Uptake and subcellular distribution of radiolabeled polymersomes for radiotherapy
por: Roobol, Stefan J., et al.
Publicado: (2020)